SF Pharma Achieves New Breakthrough In Service Model Of End To End Pharmaceutical Supply Chain
The supply chain is a system, alllinks are connected through the process, starting from the downstream customerdemand, gradually to the upstream demand forecast planning, material andequipment procurement, production assembly, inventory and distribution, andfinally to the customer. Optimizing end to end pharmaceutical supply chain isthe ultimate goal of the overall goal, implementing lean management, connectingall supply chain activities and optimizing, each node needs to cooperate witheach other is the key to ensure timely delivery, reduce supply operation costs,improve working capital (reduce inventory and sluggishness), reduce shortagesand increase revenue, accurately predict and ensure quality (reduce returns),reduce waste and reduce costs while improving supply stability.
On January 1, 2020, the"Shenzhen Vaccine Warehousing Project" co-operated by SF Pharma and avaccine benchmarking company was successfully launched. It marks that SFPharma's "end to end pharmaceutical supply chain service capability"has been recognized by industry giants, creating a "one-stop" servicemodel for the supply chain, providing vaccine manufacturers with traceability management,quality compliance, and marketing channels throughout the chain. Provideall-round support in terms of empowerment, warehouse distribution, costreduction and efficiency enhancement. "Shenzhen Vaccine WarehousingProject" is one of the key nodes of SF Pharma's end to end pharmaceuticalsupply chain service capability". SF Pharma provides Shenzhen GMP extendedwarehouse operation services for the vaccine manufacturer, covering warehouselocation selection, customized transformation, joint drug regulatory filing anddaily operation management, etc. After getting through the "Shenzhen GMPextension warehouse" link, SF Pharma created a domestic supply chain"one-stop service mode" : "vaccine semi-finished producttransportation → factory extension warehouse operation → factory allocation andfeeding → finished product warehouse operation → trunk transportation →DCoperation → landing distribution".
The "one-stop" supplychain service, from vaccine raw material transportation to vaccine finishedproduct terminal distribution and reverse marketing and allocation, has passedthe high-standard and demanding audit of customers, and also meets theregulatory requirements of competent authorities, creating extensive value forenterprises and society.
1. The whole process of vaccinequality and safety can be traced back
Through the whole-processinformation system solution covering warehousing and distribution system, datadisplay, interface and chassis system, combined with the whole-processmonitoring and early warning of cargo temperature/ambient temperature, and thevisual tracking of vehicles, the unified management of warehousing anddistribution and information traceability can be effectively realized,guaranteeing Vaccine storage safety, distribution safety, use safety andinformation traceability.
2. Whole-process compliancemanagement
Based on its experience in thefiling of prescription drug warehouses, a sound quality management system, andstandardized operation management, SF Pharma helps vaccine manufacturers tocomplete the filing of remote warehouses, site equipment compliancecertification, and full operation compliance.
3. Marketing channel sinkingempowerment
Through neutral and professionalintegrated logistics services of warehouse and distribution, we can helpvaccine manufacturers to set up optimal front-end warehouses to meet the needsof marketing channels sinking, and to get closer to the customer terminal ofthe recipient, shorten the delivery mileage, effectively improve the deliverytimeliness covering cities, reduce breakage rate and reduce overall logisticscosts.
4. Customized value-added services
According to customer needs, SFPharma provides customized in-store operation services, IT systemtransformation/interconnection, cold chain packaging material usage andrecycling management and other value-added services.
5. Ensure the safety of vaccinecirculation
Relying on SF's high-qualityservice and good reputation, it has further won the trust of the public on thebasis of ensuring the quality and safety of vaccines throughout the process oftransportation and storage.
With the smooth progress of thecooperation model of "end to end pharmaceutical supply chain", SFPharma will continue to provide executable and referable industry standards forvaccine manufacturers and CENTERS for Disease control and Prevention at alllevels to ensure the safety of vaccine circulation and create continuous valuefor enterprises and society. Through the effective management of end to endpharmaceutical supply chain, suppliers and customers are included in the wholesupply chain management system, which will find more opportunities to eliminatelosses, achieve a win-win situation with suppliers and customers, and greatlyreduce the operation cost of the supply chain. At the same time, the inventoryand reaction speed of finished products are reduced, which provides the companywith more sufficient cash flow and higher order satisfaction rate, so that thecompany has more funds to invest in new projects to increase sales, and at thesame time reduces the cost of finished products, and finally maximizes profits.For the long-term development of the company to lay a solid foundation andprovide sufficient power.
Looking for chemical products? Let suppliers reach out to you!
2026-07-07
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Egyptian Pharmaceutical Market Research
-
CPHI China 2023 | At the Heart of Pharma
-
A Guide Into What the Pharmaceutical Use of Hexamine Is
-
In line with the 8201, Hengrui Pharmaceutical plans the HER2 ADC in this way
-
$50 billion in products were 'returned' to rationalize those blockbuster BD deals
-
Tronsound long-acting IL-36R antibody obtained FDA clinical IND
-
Dapagliflozin is approved in the EU for the treatment of symptomatic chronic heart failure
-
The FDA accepted Zuranolone's NDA application and granted it priority review rights for the treatment of MDD and PDD
-
Asia Hong Pharma announced that it has co-developed an innovative tumor therapy based on AI+RNA technology route with ReviR
-
Ribo Biologics announced that the world's first FIH application for a siRNA drug targeting FXI has been successfully approved by HREC in Australia
Recommend Reading
-
What is Serine? (Amino Acid Function & Sources)
-
Sulfuric Acid Reactions: With Sugar (Dehydration), Water, and Metals
-
Cayman Chemical Product Catalog: Overview, Categories & Pricing
-
Microcrystalline Cellulose: Applications in Pharmaceuticals
-
Sodium Alginate: Properties, Uses, and Benefits
-
Methanol market trend fluctuates and rises
-
Sodium Metabisulfite Prices Rise This Week in China (4.13-4.17)
-
Polyethylene Rises First, Then Falls, Yet Remains at a High Level
-
October Phosphate Market Trends: Initially Down, Then Up
-
Construction Starts Decline; Isooctanol Prices Fluctuate and Fall This Week